Calcipotriene 0.005% and betamehasone dipropionate 0.064% ointment, 60 g and 100 g
Indications and Usage:
Taclonex (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and older. Taclonex Ointment should be applied to affected areas once daily for up to 4 weeks. The maximum weekly dose should not exceed 100 g. FOR TOPICAL USE ONLY. Taclonex Ointment should not be applied to the face, axillae, or groin. Taclonex is not for oral, ophthalmic, or intravaginal use.Taclonex Ointment should not be used in patients with hypersensitivity to any of its components or atrophy at the treatment site. The safety and efficacy of Taclonex Ointment have not been evaluated in patients with known or suspected disorders of calcium metabolism. Taclonex Ointment has not been evaluated in patients with erythrodermic, exfoliative, or pustular psoriasis or in.
Side Effects and Contraindications:
Hypercalcemia and hypercalciuria have been observed with Taclonex Ointment. Reversible hypothalamic-pituitary-adrenal (HPA)-axis suppression has also been observed with Taclonex Ointment. Systemic absorption may require evaluation for HPA-axis suppression. Potent corticosteroids, use on large areas, prolonged use, or occlusive use may increase systemic absorption. Cushingís syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. In clinical trials with Taclonex Ointment, the most frequent adverse reactions were pruritus and scaly rash. Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be more likely with occlusive use or more potent corticosteroids.